Impressive progress has been made in the development of drugs that inhibit human immunodeficiency virus replication. A new study indicates that mycophenolic acid, a selective inhibitor of lymphocyte proliferation, might also be useful in controlling viral replication through several mechanisms (pages 762–768).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Gulick, R.M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy . N. Engl. J. Med. 337, 734– 739 (1997).
Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725– 733 (1997).
Palella, F.J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853–860 (1998).
Chapuis, A.G. et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nature Med. 6, 762–768 (2000).
Haase, A.T. Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17, 625–656 (1999).
Chun, T.-W. et al. Fate of HIV-1-infected T cells in vivo: Rates of transition to stable latency. Nature Med. 1, 1284– 1290 (1995).
Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627–1632 (1999).
Margolis, D. et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21, 362– 370 (1999).
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291– 1295 (1997).
Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).
Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512– 517 (1999).
Lori, F. et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266, 801– 805 (1994).
Lori, F. et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180, 1827–1832 ( 1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Finzi, D., Siliciano, R. Taking aim at HIV replication. Nat Med 6, 735–736 (2000). https://doi.org/10.1038/77444
Issue Date:
DOI: https://doi.org/10.1038/77444
